An­tios Ther­a­peu­tic­s' hep B can­di­date gets an­oth­er round of ap­plause from in­vestors, clos­ing out a $171M megaround

An­tios Ther­a­peu­tics, the At­lanta biotech that was the brain­child of for­mer hep C pi­o­neer Phar­mas­set ex­ec­u­tive and for­mer An­tios CEO Abel De La Rosa, an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER